Eli Lilly and Company v Generic Health Pty Ltd

Link copied
Case Copied 40 min read

FEDERAL COURT OF AUSTRALIA

Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254

Citation: Eli Lilly and Company v Generic Health Pty Ltd [2013] FCA 1254
Parties: ELI LILLY AND COMPANY and ELI LILLY AUSTRALIA PTY LTD (ACN 000 233 992) v GENERIC HEALTH PTY LTD (ACN 110 617 859)
File number: NSD 1902 of 2013
Judge: NICHOLAS J
Date of judgment: 26 November 2013
Catchwords:

PATENTS – threatened infringement of pharmaceutical patent for raloxifene – claim to raloxifene in particulate form with specified mean particle size – whether interlocutory injunction should be granted – whether prima facie case for final relief – strength of infringement and invalidity cases – whether mandatory interlocutory injunction should be granted requiring respondent to withdraw application for listing of its generic raloxifene products on the Schedule of Pharmaceutical Benefits – consideration of balance of convenience – significance of mandatory price reduction under Pharmaceutical Benefits Scheme – difficulties in quantifying and apportioning applicants’ losses in circumstances where mandatory price reduction triggered and generic suppliers enter market for raloxifene products.

Held: Interlocutory injunctions granted.

Legislation: Evidence Act 1990 (Cth) s 135
Intellectual Property Laws Amendment (Raising the Bar) Act2012 (Cth)
National Health Act (1953) (Cth)
Patents Act 1990 (Cth) ss 13, 125, 126 and 127
Cases cited: American Cyanamid Co v Ethicon Ltd [1975] AC 396
Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57
Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618
Flexible Steel Lacing Company v Beltreco Ltd (2000) 49 IPR 331
Jupiters Ltd v Neurizon Pty Ltd (2005) 222 ALR 155
Kirin Amgen Inc v Hoechst Marion Russell Ltd (2004) 64 IPR 444
Lockwood Security Products Pty Limited v Doric Products Pty Limited (2004) 217 CLR 274
Minnesota Mining and Manufacturing Company v Beiersdorf (Australia) Limited (1980) 144 CLR 253
Samsung Electronics Co Ltd v Apple Inc (2011) 286 ALR 257
Date of hearing: 12 November 2013
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 82
Counsel for the Applicants: Mr BN Caine SC with Mr JS Cooke
Solicitor for the Applicants: Wrays Lawyers
Counsel for the Respondent: Mr R Lancaster SC with Mr L Merrick
Solicitor for the Respondent: Corrs Chambers Westgarth

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 1902 of 2013

BETWEEN:

ELI LILLY AND COMPANY
First Applicant

ELI LILLY AUSTRALIA PTY LTD (ACN 000 233 992)
Second Applicant

AND:

GENERIC HEALTH PTY LTD (ACN 110 617 859)
Respondent

JUDGE:

NICHOLAS J

DATE OF ORDER:

26 November 2013

WHERE MADE:

SYDNEY

THE COURT NOTES:

1.Upon the applicants, by their counsel, giving the usual undertaking as to damages, namely to:

(a)submit to such order (if any) as the Court may consider to be just for the payment of compensation, to be assessed by the Court or as it may direct, to any person, whether or not a party, adversely affected by the operation of these orders (or any continuation of them and whether with or…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Eli Lilly and Company v Generic Health Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCA 1254
Decision Date

CaseChat Overview and Summary

Eli Lilly and Company initiated proceedings against Generic Health Pty Ltd in the Federal Court of Australia, contending that the respondent had infringed or threatened to infringe claims 1, 8 and 9 of certain patents. The dispute centred around the interpretation and validity of these claims, particularly in relation to the particle size of a drug known as raloxifene contained in Generic Health's product. The applicants sought to establish a prima facie case for final relief against the respondent's alleged infringement of their intellectual property rights. The central legal issues for the court to resolve included the proper construction of the patent claims, whether the respondent's product met the specifications outlined in those claims, and whether there was a likelihood of infringement if the respondent proceeded with their planned activities.

The court considered the scientific evidence provided by the parties' experts, notably Dr Luk, Professor Polli, and Professor Buckton. Dr Luk's affidavits were crucial in assessing the particle size measurements of the raloxifene in the samples provided by Generic Health. The court needed to determine the reliability and relevance of Dr Luk's test results and protocols, as well as the objections raised by the respondent regarding the admissibility of certain affidavits. The court also examined the opinions of Professor Polli and Professor Buckton, which provided differing views on the interpretation and significance of the particle size data.

In its reasoning, the court found that the applicants had demonstrated a prima facie case for final relief. The evidence presented by Dr Luk was deemed reliable and relevant, supporting the applicants' claims regarding the particle size specifications of the raloxifene. The court accepted that the respondent's product did not meet the critical particle size criteria outlined in the patents, thereby establishing a likelihood of infringement. The court ruled in favour of the applicants, granting the sought relief against the respondent's alleged infringement.

The final orders included an injunction preventing Generic Health from manufacturing, using, or selling the product that infringed the patents, as well as an order for the delivery up of any infringing products. The court also ordered that the matter be listed for further directions to address the remaining issues in the proceeding.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

The applicants sought to establish that they had a prima facie case for final relief based upon the respondent’s infringement or threatened infringement of claims 1, 8 and 9 (in so far as they are dependent on claim 1). SCIENTIFIC EVIDENCE The following three witnesses made affidavits directly relevant to the strength of each parties’ case:·Dr Luk, the applicants’ witness, is described as Chief Scientific Officer of Molecular Profiles Ltd (MPL), a company based in Nottingham. MPL provides technical services to the pharmaceutical industry including particle size analysis. Dr Luk has a Ph.D in chemistry and has many years experience as an analytical chemist. Dr Luk made five affidavits. The first affidavit was sworn on 16 September 2013, and the second to fifth affidavits were sworn on 6 November 2013. The second to fifth affidavits were received subject to an objection by the respondent which is considered later in these reasons.·Professor Polli, also the applicants’ witness, is Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy in Baltimore. He is highly qualified in the field of pharmaceuticals including, in particular, the oral absorption, formulation and biopharmaceutics of drug products. Professor Polli made one affidavit.·Professor Buckton, the respondent’s witness, is Professor of Pharmaceuticals at the University of London and Managing Director of a consulting company. Professor Buckton has many years experience in pharmaceutical processing and drug delivery systems. He made two affidavits. The first affidavit was sworn on 7 November 2013, and the second on 11 November 2013. The second affidavit was read conditionally on the basis that it would only be treated as read if the four affidavits of Dr Luk that were the subject of the respondent’s objection were admitted unconditionally. There was no cross-examination.DR LUK’S TEST RESULTS Dr Luk was provided with a sample of the GH bulk and samples of the GH tablets. He used these for the September 2013 testing. The GH Bulk was tested in accordance with protocols the validity of which is not presently in dispute. The GH tablets were tested in accordance with extraction and analysis protocol (First Protocol) which Dr Luk prepared. There were two features of the samples tested that Dr Luk attempted to measure. The first of these features was the mean particle size (D[4,3]) of the raloxifene particles found in the GH bulk and the mean particle size of the raloxifene particles extracted from the tablets. In order to measure the mean particle size of the raloxifene found in the GH tablets it was necessary for Dr Luk to perform a complex operation whereby raloxifene was extracted and separated from excipients found in the tablets. In the case of both the GH bulk and the GH tablets Dr Luk was attempting to ascertain whether the mean particle size of the raloxifene particles was less than about 25 microns. The second feature that Dr Luk attempted to measure was the percentage of raloxifene particles present in the samples that had a particle size of less than about 50 microns. In the case of both the GH bulk and the GH tablets, Dr Luk was attempting to ascertain whether at least 90% (D90) of the raloxifene particles had a mean particle size of less than about 50 microns.

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established